表紙
市場調査レポート

自己免疫疾患:パイプラインレビュー

Autoimmune Disorders - Pipeline Review, H2 2013

発行 Global Markets Direct 商品コード 272305
出版日 ページ情報 英文 734 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
自己免疫疾患:パイプラインレビュー Autoimmune Disorders - Pipeline Review, H2 2013
出版日: 2013年07月31日 ページ情報: 英文 734 Pages
概要

当レポートでは、自己免疫疾患の治療パイプラインの概要を提供しており、治療開発に関する情報、最新アップデート、後期開発段階・中止プロジェクトについての特集、治療開発に関わる主要企業のレビューなどをまとめ、概略下記の構成で取り上げております。

第1章 目次

第2章 イントロダクション

第3章 自己免疫疾患のスナップショット

  • 事業概説

第4章 自己免疫疾患:研究開発の概要

  • 主な治療領域

第5章 自己免疫疾患:パイプラインレビュー

  • パイプライン製品:開発段階別
  • パイプライン製品:単剤療法
  • パイプライン製品:併用療法モダリティ

第6章 自己免疫疾患パイプライン製品の概要

  • 自己免疫疾患:フェーズ?のパイプライン
  • 自己免疫疾患:フェーズ?のパイプライン
  • 自己免疫疾患:前臨床のパイプライン

第7章 自己免疫疾患:薬剤プロファイル

  • 製品1
    • 製品概説
    • 作用機序
    • R&Dの進歩

第8章 自己免疫疾患パイプラインの分析

  • 自己免疫疾患パイプライン製品:治療クラス別
  • 自己免疫疾患パイプライン製品:標的別
  • 自己免疫疾患パイプライン:投与経路別
  • 自己免疫疾患パイプライン:分子タイプ別

第9章 自己免疫疾患:最新パイプラインアップデート

第10章 自己免疫疾患:休止中のパイプラインプロジェクト

  • 休止中プロジェクトの特徴

第11章 自己免疫疾患:中断されたパイプライン製品

  • 中断パイプライン製品のプロファイル

第12章 自己免疫疾患:特集ニュース

第13章 自己免疫疾患ステートメント

第14章 世界市場の直接調査手法

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC3811IDB

Global Markets Direct's, 'Autoimmune Disorders - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Autoimmune Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Autoimmune Disorders. Autoimmune Disorders - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Autoimmune Disorders.
  • A review of the Autoimmune Disorders products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Autoimmune Disorders pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Autoimmune Disorders.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Autoimmune Disorders pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Autoimmune Disorders Overview
  • Therapeutics Development
  • Autoimmune Disorders Therapeutics under Development by Companies
  • Autoimmune Disorders Therapeutics under Investigation by Universities/Institutes
  • Late Stage Products
  • Mid Clinical Stage Products
  • Early Clinical Stage Products
  • Discovery and Pre-Clinical Stage Products
  • Autoimmune Disorders Therapeutics - Products under Development by Companies
  • Autoimmune Disorders Therapeutics - Products under Investigation by Universities/Institutes
  • Companies Involved in Autoimmune Disorders Therapeutics Development
  • Autoimmune Disorders - Therapeutics Assessment
  • Drug Profiles
  • Autoimmune Disorders Therapeutics - Drug Profile Updates
  • Autoimmune Disorders Therapeutics - Discontinued Products
  • Autoimmune Disorders Therapeutics - Dormant Products
  • Autoimmune Disorders - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products Under Development for Autoimmune Disorders, H2 2013
  • Products under Development for Autoimmune Disorders - Comparative Analysis, H2 2013
  • Number of Products under Development by Companies, H2 2013
  • Number of Products under Development by Companies, H2 2013 (Contd..1)
  • Number of Products under Development by Companies, H2 2013 (Contd..2)
  • Number of Products under Development by Companies, H2 2013 (Contd..3)
  • Number of Products under Development by Companies, H2 2013 (Contd..4)
  • Number of Products under Development by Companies, H2 2013 (Contd..5)
  • Number of Products under Development by Companies, H2 2013 (Contd..6)
  • Number of Products under Development by Companies, H2 2013 (Contd..7)
  • Number of Products under Development by Companies, H2 2013 (Contd..8)
  • Number of Products under Development by Companies, H2 2013 (Contd..9)
  • Number of Products under Development by Companies, H2 2013 (Contd..10)
  • Number of Products under Development by Companies, H2 2013 (Contd..11)
  • Number of Products under Development by Companies, H2 2013 (Contd..12)
  • Number of Products under Development by Companies, H2 2013 (Contd..13)
  • Number of Products under Development by Companies, H2 2013 (Contd..14)
  • Number of Products under Development by Companies, H2 2013 (Contd..15)
  • Number of Products under Development by Companies, H2 2013 (Contd..16)
  • Number of Products under Development by Companies, H2 2013 (Contd..17)
  • Number of Products under Development by Companies, H2 2013 (Contd..18)
  • Number of Products under Development by Companies, H2 2013 (Contd..19)
  • Number of Products under Development by Companies, H2 2013 (Contd..20)
  • Number of Products under Development by Companies, H2 2013 (Contd..21)
  • Number of Products under Development by Companies, H2 2013 (Contd..22)
  • Number of Products under Development by Companies, H2 2013 (Contd..23)
  • Number of Products under Development by Companies, H2 2013 (Contd..24)
  • Number of Products under Development by Companies, H2 2013 (Contd..25)
  • Number of Products under Development by Companies, H2 2013 (Contd..26)
  • Number of Products under Development by Companies, H2 2013 (Contd..27)
  • Number of Products under Development by Companies, H2 2013 (Contd..28)
  • Number of Products under Development by Companies, H2 2013 (Contd..29)
  • Number of Products under Development by Companies, H2 2013 (Contd..30)
  • Number of Products under Development by Companies, H2 2013 (Contd..31)
  • Number of Products under Investigation by Universities/Institutes, H2 2013
  • Number of Products under Investigation by Universities/Institutes, H2 2013 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H2 2013 (Contd..2)
  • Comparative Analysis by Late Stage Development, H2 2013
  • Comparative Analysis by Mid Clinical Stage Development, H2 2013
  • Comparative Analysis by Early Clinical Stage Development, H2 2013
  • Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013
  • Products under Development by Companies, H2 2013
  • Products under Development by Companies, H2 2013 (Contd..1)
  • Products under Development by Companies, H2 2013 (Contd..2)
  • Products under Development by Companies, H2 2013 (Contd..3)
  • Products under Development by Companies, H2 2013 (Contd..4)
  • Products under Development by Companies, H2 2013 (Contd..5)
  • Products under Development by Companies, H2 2013 (Contd..6)
  • Products under Development by Companies, H2 2013 (Contd..7)
  • Products under Development by Companies, H2 2013 (Contd..8)
  • Products under Development by Companies, H2 2013 (Contd..9)
  • Products under Development by Companies, H2 2013 (Contd..10)
  • Products under Development by Companies, H2 2013 (Contd..11)
  • Products under Development by Companies, H2 2013 (Contd..12)
  • Products under Development by Companies, H2 2013 (Contd..13)
  • Products under Development by Companies, H2 2013 (Contd..14)
  • Products under Development by Companies, H2 2013 (Contd..15)
  • Products under Development by Companies, H2 2013 (Contd..16)
  • Products under Development by Companies, H2 2013 (Contd..17)
  • Products under Development by Companies, H2 2013 (Contd..18)
  • Products under Development by Companies, H2 2013 (Contd..19)
  • Products under Development by Companies, H2 2013 (Contd..20)
  • Products under Development by Companies, H2 2013 (Contd..21)
  • Products under Development by Companies, H2 2013 (Contd..22)
  • Products under Development by Companies, H2 2013 (Contd..23)
  • Products under Development by Companies, H2 2013 (Contd..24)
  • Products under Development by Companies, H2 2013 (Contd..25)
  • Products under Development by Companies, H2 2013 (Contd..26)
  • Products under Development by Companies, H2 2013 (Contd..27)
  • Products under Development by Companies, H2 2013 (Contd..28)
  • Products under Development by Companies, H2 2013 (Contd..29)
  • Products under Development by Companies, H2 2013 (Contd..30)
  • Products under Development by Companies, H2 2013 (Contd..31)
  • Products under Development by Companies, H2 2013 (Contd..32)
  • Products under Development by Companies, H2 2013 (Contd..33)
  • Products under Development by Companies, H2 2013 (Contd..34)
  • Products under Development by Companies, H2 2013 (Contd..35)
  • Products under Development by Companies, H2 2013 (Contd..36)
  • Products under Development by Companies, H2 2013 (Contd..37)
  • Products under Development by Companies, H2 2013 (Contd..38)
  • Products under Development by Companies, H2 2013 (Contd..39)
  • Products under Development by Companies, H2 2013 (Contd..40)
  • Products under Development by Companies, H2 2013 (Contd..41)
  • Products under Development by Companies, H2 2013 (Contd..42)
  • Products under Development by Companies, H2 2013 (Contd..43)
  • Products under Development by Companies, H2 2013 (Contd..44)
  • Products under Development by Companies, H2 2013 (Contd..45)
  • Products under Development by Companies, H2 2013 (Contd..46)
  • Products under Development by Companies, H2 2013 (Contd..47)
  • Products under Development by Companies, H2 2013 (Contd..48)
  • Products under Development by Companies, H2 2013 (Contd..49)
  • Products under Development by Companies, H2 2013 (Contd..50)
  • Products under Development by Companies, H2 2013 (Contd..51)
  • Products under Development by Companies, H2 2013 (Contd..52)
  • Products under Development by Companies, H2 2013 (Contd..53)
  • Products under Development by Companies, H2 2013 (Contd..54)
  • Products under Investigation by Universities/Institutes, H2 2013
  • Products under Investigation by Universities/Institutes, H2 2013 (Contd..1)
  • Products under Investigation by Universities/Institutes, H2 2013 (Contd..2)
  • Products under Investigation by Universities/Institutes, H2 2013 (Contd..3)
  • Alcon, Inc., H2 2013
  • Bristol-Myers Squibb Company, H2 2013
  • Genzyme Corporation, H2 2013
  • Baxter International Inc., H2 2013
  • Johnson & Johnson, H2 2013
  • Boehringer Ingelheim GmbH, H2 2013
  • F. Hoffmann-La Roche Ltd., H2 2013
  • Kyowa Hakko Kirin Co., Ltd., H2 2013
  • Biogen Idec Inc., H2 2013
  • Shionogi & Co., Ltd., H2 2013
  • Valeant Pharmaceuticals International, H2 2013
  • Amgen Inc., H2 2013
  • Antares Pharma, Inc., H2 2013
  • Sanofi-Aventis, H2 2013
  • AstraZeneca PLC, H2 2013
  • Eli Lilly and Company, H2 2013
  • GlaxoSmithKline plc, H2 2013
  • Echo Therapeutics, Inc., H2 2013
  • Genentech, Inc., H2 2013
  • Inovio Biomedical Corporation, H2 2013
  • MedImmune LLC, H2 2013
  • Isis Pharmaceuticals, Inc., H2 2013
  • Biotest AG, H2 2013
  • Merck & Co., Inc., H2 2013
  • Stiefel Laboratories, Inc., H2 2013
  • Santen Pharmaceutical Co., Ltd., H2 2013
  • Ablynx, H2 2013
  • AbGenomics International, Inc., H2 2013
  • Emergent BioSolutions Inc., H2 2013
  • Novo Nordisk A/S, H2 2013
  • Cytokine PharmaSciences, Inc., H2 2013
  • Infinity Pharmaceuticals, Inc., H2 2013
  • Plexxikon Inc., H2 2013
  • XenoPort, Inc., H2 2013
  • ViaCord, H2 2013
  • BioLineRx, Ltd., H2 2013
  • ApoPharma, H2 2013
  • FibroGen, Inc., H2 2013
  • arGentis Pharmaceuticals, LLC, H2 2013
  • Reliance Life Sciences Pvt. Ltd., H2 2013
  • Piramal Healthcare Limited, H2 2013
  • MediGene AG, H2 2013
  • Celltrion, Inc., H2 2013
  • Apitope International NV, H2 2013
  • Nycomed International Management GmbH, H2 2013
  • TiGenix NV, H2 2013
  • Pacira Pharmaceuticals, Inc., H2 2013
  • Novartis AG, H2 2013
  • Isotechnika Pharma Inc., H2 2013
  • Samyang Corporation, H2 2013
  • Actelion Ltd, H2 2013
  • Astellas Pharma Inc., H2 2013
  • Biocon Limited, H2 2013
  • BioMarin Pharmaceutical Inc., H2 2013
  • Chugai Pharmaceutical Co. Ltd, H2 2013
  • Daewoong Pharmaceutical Co., Ltd., H2 2013
  • Eisai Co., Ltd., H2 2013
  • Elan Corporation, plc, H2 2013
  • Gedeon Richter Plc., H2 2013
  • Glenmark Pharmaceuticals Ltd., H2 2013
  • GTC Biotherapeutics, Inc., H2 2013
  • Japan Tobacco Inc., H2 2013
  • LEO Pharma A/S, H2 2013
  • Ono Pharmaceutical Co., Ltd., H2 2013
  • Pfizer Inc., H2 2013
  • Ranbaxy Laboratories Limited, H2 2013
  • Rigel Pharmaceuticals, Inc., H2 2013
  • Santarus, Inc., H2 2013
  • Teva Pharmaceutical Industries Limited, H2 2013
  • Toyama Chemical Co. Ltd, H2 2013
  • UCB Group, H2 2013
  • Zydus Cadila Healthcare Limited, H2 2013
  • Cell Therapeutics, Inc., H2 2013
  • Genmab A/S, H2 2013

List of Figures

  • Number of Products under Development for Autoimmune Disorders, H2 2013
  • Products under Development for Autoimmune Disorders - Comparative Analysis, H2 2013
  • Products under Development by Companies, H2 2013
  • Products under Investigation by Universities/Institutes, H2 2013
  • Late Stage Products, H2 2013
  • Mid Clinical Stage Products, H2 2013
  • Early Clinical Stage Products, H2 2013
  • Discovery and Pre-Clinical Stage Products, H2 2013
  • Assessment by Monotherapy Products, H2 2013
  • Assessment by Combination Products, H2 2013
  • Assessment by Route of Administration, H2 2013
  • Assessment by Stage and Route of Administration, H2 2013
  • Assessment by Molecule Type, H2 2013
  • Assessment by Stage and Molecule Type, H2 2013
Back to Top